Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model
Pemetrexed is a systemic chemotherapeutic agent used in the treatment of malignant mesothelioma. This drug represents a potentially promising intraperitoneal (IP) agent to use for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal mesothelioma. However, this has yet to be supported by preclinical studies. Therefore, we aimed to study the effect of pemetrexed dose and perfusion temperature on the resultant pemetrexed concentration in 3 different compartments (systemic circulation, portal circulation and peritoneal tissues) using a murine model.
Source: Surgical Oncology - Category: Surgery Authors: David Badrudin, Camille Perrault-Mercier, Antoine Bouchard-Fortier, Julien Hubert, Fran çois A. Leblond, Lucas Sideris, Pierre Dubé Source Type: research
More News: Alimta | Asbestosis | Cancer & Oncology | Chemotherapy | Mesothelioma | Perfusion | Study | Surgery